Hepatocellular carcinoma diagnosis: Circulating microRNAs emerge as robust biomarkers  by Gougelet, Angélique & Colnot, Sabine
Clinics and Research in Hepatology and Gastroenterology (2016) 40,  367—369
Available  online  at
ScienceDirect
www.sciencedirect.com
EDITORIAL
Hepatocellular  carcinoma  diagnosis:
Circulating  microRNAs  emerge  as  robust
biomarkers
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wHepatocellular  carcinoma  (HCC)  constitutes  the  second
cause  of  death  related  to  cancer  worldwide,  mainly  due  to
a  late  diagnosis  for  advanced  cancers,  and  a  non-optimal
detection  for  small  tumors.  This  bad  prognosis  is  also  a
consequence  of  the  few  therapeutic  options  available.  It
thus  appears  crucial  to  identify  new  biomarkers  to  improve
HCC  treatment  and  diagnosis.  Nowadays,  HCC  detection
is  based  on  functional  imaging,  i.e.  ultrasonography,  mag-
netic  resonance  imaging  or  positron  emission  tomography.
In  addition,  the  measurement  of  -fetoprotein  (AFP)  could
also  constitute  an  option  for  liver  tumor  diagnosis  ([1]  for
a  review).  However,  these  techniques  are  not  appropriate
for  the  smallest  tumors,  and  also  show  limited  sensitivity
and  speciﬁcity.  These  recent  years,  microRNAs  (miRNAs)
have  emerged  as  potent  diagnostic  and  prognostic  tools.
These  small  non-coding  RNAs  were  identiﬁed  as  key  reg-
ulators  of  mRNA  expression  via  translation  inhibition  and
mRNA  degradation  ([2]  for  a  review).  They  are  key  players  of
tumorigenesis,  with  either  tumor  suppressive  or  oncogenic
activity,  since  50%  miRNAs  are  located  in  sites  disrupted  or
ampliﬁed  in  cancer  [3].  A  number  of  reports  devoted  to
miRNAs  have  highlighted  these  molecules  as  potent  mark-
ers  of  tumor  cells,  with  a  microRNA  signature  identiﬁed
for  each  type  of  cancerous  lesion  [4,5].  Concerning  HCC,
different  studies  agreed  that  these  tumors  are  character-
ized  by  a  loss  of  miR-122,  Let-7  or  miR-101,  and  inversely
by  an  increase  in  miR-21,  miR-221  and  miR-224  level  ([6]
for  a  review).  More  interestingly,  miRNAs  could  also  be
valuable  non-invasive  biomarkers  in  various  biological  ﬂu-
ids  like  serum,  plasma,  urine  or  saliva.  Cell-free  miRNAs
could  be  associated  to  proteins  like  Argonaute  2,  or  lipid
structures,  either  high-  or  low-density  lipoproteins,  but  also
encapsulated  into  membrane  vesicles  like  microparticles  or
exosomes  [7].  Hepatic  exosomes  are  characterized  by  clas-
sical  markers  like  CD81  and  CD63,  but  could  also  incorporate
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2210-7401/© 2016 Elsevier Masson SAS. All rights reserved.ther  components  required  for  liver-speciﬁc  metabolic  func-
ions,  i.e.  in  lipid,  carbohydrate  and  xenobiotic  metabolisms
8]. A  growing  number  of  reports  have  shown  that  hepa-
ocellular  carcinoma-derived  exosomes  could  modify  their
rowth,  motility  and  response  to  treatment  [9—11]. In  addi-
ion,  it  has  been  shown  that  tumoral  cells,  from  different
issular  origin,  secrete  a  larger  amount  of  exosomes  than
on-tumoral  ones,  and  that  the  materials  incorporated,
ncluding  miRNAs,  could  be  modiﬁed  [12].  Concerning  cir-
ulating  miRNAs  in  HCC,  it  has  been  described  that  miR-21,
iR-221,  miR-222  and  miR-122  levels  were  deregulated  in
he  serum  of  patients  [13—15]. The  reason  why  miR-122  is
ecreased  in  liver  tumors  and  increased  in  patient  sera  is
ot  elucidated  yet.  Regarding  all  these  observations,  efforts
ave  been  conducted  these  recent  years  to  proﬁle  miRNAs
etectable  in  patient  serum,  and  which  could  be  useful  for
CC  diagnosis.  These  studies  have  been  enriched  by  two
anuscripts,  published  this  year  in  Clinics  and  Research  in
epatology  and  Gastroenterology, which  demonstrate  the
otency  of  miRNA  detection  in  serum  to  improve  the  diag-
osis  of  early-stage  and  small  tumors  in  particular.
These  two  studies  have  been  performed  on  a  signiﬁcant
ohort  of  tumors  collected  in  China  (50  HCC  patients  for
huang  et  al.  and  112  for  Lin  et  al.),  and  the  robustness
f  miRNA-based  diagnosis  was  assessed  with  serum  AFP  as
 reference  in  both  manuscripts.  The  study  of  Lin  et  al.
ocused  on  miR-224,  a miRNA  intensively  studied  in  HCC  in
ast.  MiR-224  is  described  as  an  oncomiR  in  HCC,  due  to  its
ro-proliferative  activity  via  AKT  and  SMAD4  deregulation
16,17],  and  its  pro-migratory  role  [18].  MiR-224  has  also
een  successfully  detected  in  patient  sera,  and  increases
hen  HCC  develops  following  hepatitis  B  virus  (HBV)  infec-
ion  [19,20].  The  present  work  of  Lin  et  al.  conﬁrmed  the
nduction  of  miR-224  in  early-stage  HBV-associated  tumors
s  well  as  in  serum.  MiR-224  detection  was  thus  a  more
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aluable  diagnostic  biomarker  than  AFP  measurement.  They
lso  observed  that  the  co-detection  of  AFP  with  miR-224
llows  the  discrimination  of  HCC  from  hepatitis  B  patients
nd  healthy  controls  with  the  best  accuracy  as  revealed  by
UC  (area  under  the  ROC  curve),  sensitivity  and  speciﬁcity
>0,85,  87%  and  76%  in  both  cases,  respectively).  Interest-
ngly,  their  data  showed  that  this  microRNA  was  produced
rom  tumors,  since  its  expression  in  serum  was  normalized
fter  tumor  resection.
The  work  of  Zhuang  et  al.  assessed  the  accuracy  of
irculating  miR-21,  miR-101  and  miR-26a,  three  miRNAs
eregulated  in  HCC,  for  HBV-associated  tumor  diagnosis.
iR-21  is  described  as  upregulated  in  HCC  tumors,  while
iR-101  and  miR-26a  are  downregulated.  These  miRNAs
ontrol  different  aspects  of  HCC  progression,  i.e.  cell  pro-
iferation,  via  EZH2  repression  for  miR-101  and  miR-26a
17,21],  or  PTEN  downregulation  for  miR-21  [22], apo-
tosis  [23],  and  epithelial-to-mesenchymal  transition  [24].
he  expression  of  these  miRNAs  is  similarly  deregulated
n  serum:  miR-101  and  miR-26a  are  impaired  following
BV-associated  HCC  development  [25,26],  while  miR-21  is
pregulated  in  hepatitis  B  and  C-induced  HCC  [27]. In  their
resent  study,  Zhuang  et  al.  corroborate  the  induction  of
iR-21  and  the  downregulation  of  miR-101  and  miR-26a  in
he  serum  of  HCC  patients  as  compared  to  healthy  donors
nd  hepatitis  patients.  Surprisingly,  they  could  show  that
iR-21  was  efﬁciently  impaired  following  tumor  resection,
hile  miR-101  and  miR-26a  expression  was  not  modiﬁed
fter  surgery.  This  suggests  that  some  circulating  miRNAs,
uch  as  miR-21,  have  a  tumoral  origin  but  others,  like  miR-
01  and  miR-26a,  could  emerge  from  non-tumoral  cells.
evertheless,  they  could  promisingly  show  that  the  quan-
iﬁcation  of  miR-101/miR-26a/miR-21  in  serum  is  a  better
iagnosis  tool  than  AFP  alone.  As  described  for  miR-224
y  the  work  of  Lin  et  al.,  they  observed  the  best  perfor-
ance  for  the  combination  of  these  three  miRNAs  with  AFP
n  terms  of  AUC,  sensitivity  and  speciﬁcity  as  compared
o  healthy  controls  (AUC  =  0.914,  sensitivity  87%,  speciﬁcity
8%).  However,  as  mentioned  this  year  by  a  paper  of  Sohn
t  al.  [20],  miR-21  was  not  signiﬁcantly  different  between
CC  patients  and  those  affected  by  HBV.  They  thus  suc-
essfully  discriminate  HCC  from  HBV  patients  according
o  miR-101/miR-26a  only.  Once  again,  the  combination  of
hese  two  miRNAs  with  AFP  constitutes  the  best  option
AUC  =  0.854,  sensitivity  72.5%,  speciﬁcity  86.7%).  Promis-
ngly,  when  the  authors  focused  their  study  on  small  tumors
<3  cm),  they  highlighted  that  the  association  of  circulat-
ng  miR-26a  with  AFP  was  reliable  to  differentiate  HCC
atients  from  those  with  hepatitis  (AUC  =  0.824,  sensitivity
4%,  speciﬁcity  76.7%).  This  is  of  great  interest  since,  in
ase  of  small  tumors,  AFP  measurement  is  not  sufﬁcient  to
iscriminate  small  tumors  from  HBV  patients.  These  results
ompare  with  those  obtained  by  Lin  et  al.  with  the  combi-
ation  miR-224/AFP,  which  could  successfully  discriminate
arly-stage  HCC  from  HBV  patients  (AUC  =  0.87,  sensitivity
7.5%,  speciﬁcity  76.5%).
Altogether,  these  papers  strongly  support  the  great  bene-
t  of  circulating  miRNAs  to  detect  HCC  at  very  early  stages,
ven  if  these  encouraging  data  had  to  be  conﬁrmed  on  a
arger  cohort  of  samples.  In  particular,  it  appears  crucial
o  explore  if  these  data  are  speciﬁc  of  HBV-related  HCC,
r  could  be  extended  to  hepatitis  C  virus  (HCV),  NASH  orEditorial
lcohol-associated  HCC.  To  support  this  point,  miR-101  level
s  decreased  by  HBx  protein  [28],  and  thus  could  be  spe-
iﬁc  of  this  group  of  tumors,  while  miR-21  upregulation  has
een  observed  in  HBV+  as  well  as  on  HCV+  HCC  [27].  This
lariﬁcation  could  lead  to  the  identiﬁcation  of  a  panel  of
iRNAs,  differentially  deregulated  according  to  HCC  eti-
logies.  This  panel  of  miRNAs  could  be  relevant  for  the
iagnosis  of  each  molecular  subgroup  of  tumors,  and  could
avor  the  administration  of  differential  targeted  therapies  to
atients.  Although  these  two  manuscripts  agree  that  miRNA
xpression  in  serum  is  closely  correlated  to  those  observed
n  tumors,  it  remains  to  determine  the  precise  cell  origin
f  circulating  miRNAs,  since  tumor  resection  did  not  restore
he  expression  of  all  studied  miRNAs.  A  better  understanding
ould  allow  pathologists  to  support  these  miRNAs  as  potent
iomarkers,  i.e.  in  the  case  of  relapse.  Finally,  despite  the
act  that  AFP  measurement  is  unsuccessful  for  early  HCC
iagnosis,  it  appears  that  a  combination  of  AFP  with  miRNA
etection  presents  the  best  accuracy  in  terms  of  sensitivity
nd  speciﬁcity.  Regarding  to  these  two  works,  we  may  ask
f  a  combination  of  miR-224  with  miR-101/miR-26a  and  AFP
ould  not  constitute  the  optimal  panel  for  early-stage  HCC
iagnosis.
To  conclude,  besides  the  therapeutic  opportunities
erived  from  miRNAs  in  a  great  number  of  cancers,  these
mall  molecules  appear  as  very  promising  diagnosis  and
rognosis  biomarkers,  on  the  basis  of  their  detection  in
erum  but  also  in  other  body  ﬂuids  like  saliva  or  urine,  and
ive  a  hope  for  improvement  of  HCC  patient  care  in  future.
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